Similarly, Guanabenz (another eIF2α dephosphorylation inhibitor) delays disease progression in some amyotrophic lateral sclerosis (ALS) models [59], [60], but worsens it in others [61]. Here, EIF2A is linked to amyotrophic lateral sclerosis.